IL5 and asthma: Mepolizumab, reslizumab and benralizumab target the IL-5 axis and are currently undergoing efficacy evaluation administered in steroid-dependent, relapsing and/or refractory EGPA.3 In accordance with the rarity of EGPA, the aim of this case series is to report three case reports diagnosed with EGPA according to the American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria5 (Table 1) successfully treated with an anti-IL5 agent as an asthma-controlling and corticosteroid-sparing supplemental regimen.